Editorial
Is It Time for Carotid Artery Stenting in Low-Risk Patients?
Abstract
Carotid artery stenting (CAS) has been increasingly adopted as a less invasive endovascular option of carotid revascularization in varied clinical populations. The SAPPHIRE (Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy) trial1 first demonstrated the superiority of CAS using embolic protection devices over carotid endarterectomy (CEA) in high-risk patients. More recently, CREST (Carotid Revascularization Endarterectomy versus Stenting Trial)2 confirmed that there is clinical equivalence between CAS and CEA in average-risk patients. We now await the next CAS study that should intuitively focus on low-risk patients.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.